Furberg, Curt
Furberg, Curt, 1936-
Furberg, Curt D.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Curt Furberg německý kardiovaskulární epidemiolog, vysokoškolský pedagog, specialista v oblasti veřejného zdraví, bezpečnosti pacientů a hodnocení léčiv
VIAF ID: 52811740 ( Personal )
Permalink: http://viaf.org/viaf/52811740
Preferred Forms
-
100 0 _
‡a
Curt Furberg
‡c
německý kardiovaskulární epidemiolog, vysokoškolský pedagog, specialista v oblasti veřejného zdraví, bezpečnosti pacientů a hodnocení léčiv
-
100 1 _
‡a
Furberg, Curt
-
100 1 _
‡a
Furberg, Curt
-
100 1 _
‡a
Furberg, Curt
-
100 1 _ ‡a Furberg, Curt
-
100 1 _ ‡a Furberg, Curt
-
100 1 _ ‡a Furberg, Curt
-
100 1 _ ‡a Furberg, Curt (sparse)
-
100 1 _ ‡a Furberg, Curt D.
-
100 1 _
‡a
Furberg, Curt D.
-
100 1 _ ‡a Furberg, Curt D.
-
100 1 _ ‡a Furberg, Curt ‡d (1936- )
-
100 1 _ ‡a Furberg, Curt ‡d (1936- ).
-
100 1 _
‡a
Furberg, Curt
‡d
1936-
-
100 1 _
‡a
Furberg, Curt,
‡d
1936-
-
100 1 _ ‡a Furberg, Curt, ‡d 1936-
4xx's: Alternate Name Forms (6)
Works
| Title | Sources |
|---|---|
| ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents |
|
| Allt är inte guld som glimmar. |
|
| Atorvastatin reduces microalbuminuria microalbuminuria in patients with familial hypercholesterolemia an normal glucose tolerance |
|
| Boken om läkemedel, 2007: |
|
| Coronary heart disease in the elderly : Working Conference on the Recognition and Management of Coronary Heart Disease in the Elderly, held September 4-6, 1985, at the National Institutes of Health, in Bethesda, Maryland, U.S.A. |
|
| Data monitoring in clinical trials : a case studies approach |
|
| Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance |
|
| Evaluating clinical research : all that glitters is not gold |
|
| Fundamentals of clinical trials |
|
| Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis |
|
| Kardioprotektion Sekundärprophylaxe nach Herzinfarkt u. antiarrhythm. Therapie ; internat. Symposion Rottach-Egern/Tegernsee, 14. - 15. Juni 1982 |
|
| Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation |
|
| Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. |
|
| n80119620 |
|
| Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis |
|
| Preventing atherosclerosis and its complications : promising alternative for the future : proceedings of a symposium held immediatly prior the |
|
| The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study. |
|
| Recent trials in hypertension: compelling science or commercial speech? |
|
| Rinsho kenkyu o tadashiku hyokasuru niwa : Dr. Fabagu ga oshieru 26 no pointo. |
|
| Studies on an extra pre-beta lipoprotein fraction / by G. Dahlén [i 4 pozostałych]. - Boden, 1972. |
|
| Workshop on Platelet-active Drugs in the Secondary Prevention of Cardiovascular Events (1980 : National Institutes of Health). Proceedings of the Workshop ... 1980: |
|
| 臨床研究を正しく評価するには : Dr. ファーバーグが教える26のポイント |
|
| 臨床試験とは何か = What clinicians need to know about clinical trials |
|
